The current data revealed the function of LINK-A inhibition on overcoming Ibrutinib resistance in MCL cells by regulating the AKT/Bcl2 pathway, and might provide a novel target for Ibrutinib-resistant MCL patients. The gene discussed is AKT1; the disease is mantle cell lymphoma.